核因子κB与恶性血液病  

NF-κB and malignant hematologic diseases

作　　者：王少雄[1] 王少元[1] 

机构地区：[1]福建医科大学附属协和医院血液科,福建福州350001

出　　处：《国际内科学杂志》2007年第8期489-492,F0003,共5页International Journal of Internal Medicine

摘　　要：核因子κB(NF-κB)是一类重要的转录调节因子,在体内外多种因素的刺激与激活后,可转移到核内参与调节多种基因的转录表达,从而参与广泛的生物学效应。研究发现NF-κB与恶性血液肿瘤的发生、发展、预后及化疗的耐受有关。了解NF-κB的生物学功能及其与恶性血液病的关系,选择性地调控其生物学活性,可能为恶性血液病的治疗提供一个新的途径。Nuclear factor-kappa B is an important transcription factor. It can be activated by many of stimuli in vivo and in vitro and translocate to nuclei to regulate transcription of many NF-κB-mediated genes, therefore induce a wide variety of biological effects. Many studies indicate that NF-κB correlates with prognosis and drug resistance of hematologic maligancy besides neoplasma genesis and growth. We can selectively regulate NF-κB biologic activity after explore NF-κB biological functions and relations with malignant neoplastic hematologic disorders, which may become a new therapeutic approach of malignant hematologic diseases.

关 键 词：NF—κB 白血病 淋巴瘤 多发性骨髓瘤 多药耐药 化疗 

分 类 号：R730.5[医药卫生—肿瘤]